X-linked creatine transporter deficiency

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:52503OMIM:300352E72.8
Who is this for?
Show terms as
2Active trials7Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

X-linked creatine transporter deficiency (also called creatine transporter defect, CTD, or CRTR deficiency) is a rare inherited condition that affects how the brain and body use creatine. Creatine is a natural substance that cells — especially brain cells — need to produce energy. In this condition, a faulty gene means the body cannot properly move creatine into cells, so the brain is starved of the energy it needs to develop and work normally. The condition mainly affects males, though some females who carry the gene change can also have symptoms, usually milder ones. The most common signs include intellectual disability (difficulty with learning and thinking), delayed speech and language development, behavioral problems such as hyperactivity or autism-like behaviors, and seizures. Some affected individuals also have low muscle tone (floppiness) and slow physical development. There is currently no cure for X-linked creatine transporter deficiency. Treatment focuses on managing symptoms — for example, anti-seizure medicines for epilepsy, speech therapy, occupational therapy, and educational support. Creatine supplements have been tried but unfortunately do not help because the transporter needed to get creatine into brain cells is not working. Research into new treatments, including gene therapy approaches, is ongoing.

Also known as:

Key symptoms:

Intellectual disability (difficulty with learning, reasoning, and daily tasks)Delayed speech and language developmentBehavioral problems such as hyperactivity, aggression, or autism-like behaviorsSeizures (epilepsy)Low muscle tone (floppy muscles, especially in infancy)Delayed motor milestones such as sitting, standing, or walking lateShort stature or slow physical growthAttention difficulties and impulsivityMild facial features that may look slightly different from family membersAnxiety or mood problemsFeeding difficulties in infancy

Clinical phenotype terms (26)— hover any for plain English
Self-mutilationHP:0000742
Inheritance

X-linked recessive

Carried on the X chromosome; typically affects males more than females

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

4 events
Oct 2025Clinical Prospective ranDomized Trial to Evaluate the Non-inferiority of Left Bundle Branch Area Pacing Vs Cardiac ResynchronIzatioN Therapy With ECG guIded AV Optimization

Leonardo Calò, MD — NA

TrialNOT YET RECRUITING
Mar 2023Relevant Outcome Measures for Creatine Transporter Deficiency Patient

Hospices Civils de Lyon — NA

TrialRECRUITING
Oct 2022Characterization of Dysmorphology in Subjects With Creatine Transporter Deficiency

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

TrialRECRUITING
Dec 2021SLC13A5 Deficiency Natural History Study - United States Only

TESS Research Foundation — NA

TrialENROLLING BY INVITATION

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for X-linked creatine transporter deficiency.

2 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

2 recruitingView all trials with filters →
N/A1 trial
Relevant Outcome Measures for Creatine Transporter Deficiency Patient
N/A
Actively Recruiting
PI: Aurore CURIE, MD,PhD · Sites: Bron · Age: 260 yrs
Other1 trial
Characterization of Dysmorphology in Subjects With Creatine Transporter Deficiency
Actively Recruiting
PI: Laverne G Mensah, M.D. (Eunice Kennedy Shriver National Institute of Child) · Sites: Bethesda, Maryland · Age: 240 yrs

Specialists

7 foundView all specialists →
FM
Forbes D Porter, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 14 active trials
LM
Laverne G Mensah, M.D.
COLUMBUS, OH
Specialist
PI on 1 active trial
JP
Jacques Mansourati, Pr
Specialist
PI on 1 active trial
GK
Grant Kim
LOS ANGELES, CA
Specialist
PI on 1 active trial190 X-linked creatine transporter deficiency publications
IP
Ian S Ramsay, PhD
PLYMOUTH, MI
Specialist
PI on 1 active trial
SD
S Andreas, Prof. Dr
Specialist
PI on 1 active trial
BP
Brenda E Porter, MD, PhD
Palo Alto, California
Specialist

Rare Disease Specialist

PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to X-linked creatine transporter deficiency.

Search all travel grants →NORD Financial Assistance ↗

Community

Open X-linked creatine transporter deficiencyForum →

No community posts yet. Be the first to share your experience with X-linked creatine transporter deficiency.

Start the conversation →

Latest news about X-linked creatine transporter deficiency

1 articles
Clinical trialCLINICALTRIALSApr 1, 2026
Trial Now Recruiting: Optical Imaging in X-linked Disorders. (NCT06868979)
Researchers are looking for 88 people with Fragile X Syndrome or Creatine Transporter Deficiency to test a new imaging technology that can see how the brain wor
See all news about X-linked creatine transporter deficiency

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What genetic test results confirm this diagnosis, and what does the specific SLC6A8 change mean for my child's outlook?,Should other family members, especially female relatives, be tested for carrier status?,What therapies are most important to start right away, and how often should my child receive them?,Are there any clinical trials or research studies we could consider joining?,What is the best plan for managing seizures, and when should I call emergency services?,Are there any dietary supplements or experimental treatments that might help?,What support services and educational resources are available for my child and our family?

Common questions about X-linked creatine transporter deficiency

What is X-linked creatine transporter deficiency?

X-linked creatine transporter deficiency (also called creatine transporter defect, CTD, or CRTR deficiency) is a rare inherited condition that affects how the brain and body use creatine. Creatine is a natural substance that cells — especially brain cells — need to produce energy. In this condition, a faulty gene means the body cannot properly move creatine into cells, so the brain is starved of the energy it needs to develop and work normally. The condition mainly affects males, though some females who carry the gene change can also have symptoms, usually milder ones. The most common signs i

How is X-linked creatine transporter deficiency inherited?

X-linked creatine transporter deficiency follows a x-linked recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does X-linked creatine transporter deficiency typically begin?

Typical onset of X-linked creatine transporter deficiency is infantile. Age of onset can vary across affected individuals.

Are there clinical trials for X-linked creatine transporter deficiency?

Yes — 2 recruiting clinical trials are currently listed for X-linked creatine transporter deficiency on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat X-linked creatine transporter deficiency?

7 specialists and care centers treating X-linked creatine transporter deficiency are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.